Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for 5-nucleotidase syndrome has been reported in the published literature.
No clinical trials have been registered for 5-nucleotidase syndrome.
105 publications have been identified in PubMed for 5-nucleotidase syndrome. Kisho has analyzed 52 by research type. Research spans Epidemiology / Natural History (31%), Basic Science / Preclinical (21%), and Review / Meta-Analysis (19%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 16 | 31% |
Data assembled from 2 of 12 sources · Last updated Sep 18, 2026, 2:35 PM UTC
Genetic and Rare Diseases Info Center
Common questions about 5-nucleotidase syndrome
Laboratory research |
11 |
21% |
Research summaries | 10 | 19% |
Testing and diagnosis research | 7 | 13% |
Clinical study results | 5 | 10% |
New treatment approaches | 3 | 6% |
Gertz MA (2026). [PMID: 41723627](https://pubmed.ncbi.nlm.nih.gov/41723627/). *Am J Hematol*. [Review / Meta-Analysis]
Derudder R (2026). [PMID: 41376271](https://pubmed.ncbi.nlm.nih.gov/41376271/). *J Inherit Metab Dis*. [Review / Meta-Analysis]
Zhou Y (2026). [PMID: 41508418](https://pubmed.ncbi.nlm.nih.gov/41508418/). *Hematology*. [Review / Meta-Analysis]
Fantin RL (2026). [PMID: 40690383](https://pubmed.ncbi.nlm.nih.gov/40690383/). *Anesth Analg*. [Epidemiology / Natural History]
Bichali S (2026). [PMID: 40069379](https://pubmed.ncbi.nlm.nih.gov/40069379/). *Pediatr Cardiol*. [Epidemiology / Natural History]
Giorlandino C (2025). [PMID: 41272990](https://pubmed.ncbi.nlm.nih.gov/41272990/). *Brain Behav*. [Basic Science / Preclinical]
Kendzerska T (2025). [PMID: 40383186](https://pubmed.ncbi.nlm.nih.gov/40383186/). *Chest*. [Epidemiology / Natural History]
Vázquez-Ruiz Z (2025). [PMID: 40368298](https://pubmed.ncbi.nlm.nih.gov/40368298/). *J Nutr*. [Epidemiology / Natural History]
Ibrahim M (2025). [PMID: 40546647](https://pubmed.ncbi.nlm.nih.gov/40546647/). *Cureus*. [Review / Meta-Analysis]
Soliman N (2025). [PMID: 40252663](https://pubmed.ncbi.nlm.nih.gov/40252663/). *Lancet Neurol*. [Review / Meta-Analysis]
AI-curated news mentioning 5-nucleotidase syndrome
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.